Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Phase 4

Terminated

Conditions: Thrombosis
Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2012-06-06

Last Posted Date: 2018-04-26

Lead Sponsor: Indiana University

Target Recruit Count: 67

Registration Number: NCT01612884

Locations: 🇺🇸
Eskenazi Health, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2012-06-01

Last Posted Date: 2014-12-23

Lead Sponsor: Dong-A University

Target Recruit Count: 76

Registration Number: NCT01609647

Locations: 🇰🇷
DongA University Hospital, Busan, Korea, Republic of

The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

Phase 3

Conditions: Coronary Artery Disease

Interventions: Drug: Aspirin
Drug: Tirofiban
Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2012-05-15

Last Posted Date: 2012-05-15

Lead Sponsor: Prince Sultan Cardiac Center, Adult Cardiology Department.

Target Recruit Count: 200

Registration Number: NCT01598337

Locations: 🇸🇦
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia

Study of Prasugrel in Korean Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Prasugrel

First Posted Date: 2012-05-04

Last Posted Date: 2012-10-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT01591317

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Phase 3

Completed

Conditions: Coronary Artery Bypass

Interventions: Drug: Prasugrel
Drug: Placebo

First Posted Date: 2012-03-22

Last Posted Date: 2019-10-30

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 84

Registration Number: NCT01560780

Locations: 🇺🇸
Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago, Illinois, United States
🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States
🇺🇸
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States

and more 1 locations